AstraZeneca has opened its first U.S.-operated cell therapy manufacturing facility in Rockville, Maryland, as part of its ...

The medicine, Trastuzumab deruxtecan, was already available for some breast and stomach cancers. It has been approved to ...

AstraZeneca and Daiichi's Enhertu, followed by THP, has shown pCR rate improvement in the randomised DESTINY-Breast11 Phase ...

The facility, which will produce cell therapies used to treat cancer and auto immune diseases, creates 150 jobs for highly ...

AstraZeneca said on Friday its triple-combination inhaler Breztri Aerosphere met all main goals in two late-stage trials for ...

As it applies to the development of cell therapies, AstraZeneca’s chief of global operations, Pam Cheng, admits that the ...

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...

Cell therapy is considered by some as the next frontier in cancer treatment, engineering patients' own immune systems to ...

The facility to manufacture cell therapies for cancer research is part of the company's push to invest $3.5B in its U.S. operations by the end of 2026.

The company removed experimental drugs for Alzheimer’s, migraine and pain from its pipeline to focus more resources on “core ...

The drugmaker posted increased core earnings per share and sales for the first quarter, but also said it could face a fine of ...

AstraZeneca (AZN) CEO Pascal Soriot is not overly concerned about the threat of tariffs by the Trump administration on ...